CYP24A1 and prostate cancer: Thisstudy highlights the therapeutic potential of newly synthesized N-acetyl Schiff bases, particularly 6d, whichdemonstrates strong efficacy as a dual-target inhibitor with potentialapplications in prostate cancer treatment and inhibition of hCAI andhCAII enzymes.